SONIRE Therapeutics
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing a cavitation-enhanced, ultrasound-guided HIFU therapy system for minimally invasive treatment of intractable cancers, starting with pancreatic cancer.
Oncology
Technology Platform
A next-generation, cavitation-enhanced, ultrasound-guided High-Intensity Focused Ultrasound (HIFU) system designed to improve treatment speed and enable real-time visualization of the ablation zone.
Opportunities
Large unmet need in intractable cancers like pancreatic cancer, and the platform potential to expand HIFU treatment into new oncology indications beyond current urological and neurological uses.
Risk Factors
Technical risks in developing a novel, complex medical device; regulatory hurdles for a new class of therapeutic ultrasound; and future competition from established medtech companies in the image-guided therapy space.
Competitive Landscape
Competes in the therapeutic ultrasound segment against companies like Profound Medical and Insightec. Differentiation is based on cavitation-enhancement for faster treatment and improved visualization, specifically targeting deep-seated abdominal tumors.